A quest for stakeholder synchronization in the CAR T-cell therapy supply chain.

Autor:	Holland SM; Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia.; Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia., Sohal A; Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia.; Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia., Nand AA; Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia.; Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia., Hutmacher DW; Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia.; Faculty of Engineering, School of Mechanical Medical and Process Engineering, Queensland University of Technology, Brisbane, QLD, Australia.; Australian Research Council Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), Queensland University of Technology, Kelvin Grove, QLD, Australia.; Max Planck Queensland Centre, Queensland University of Technology, Brisbane, QLD, Australia.
Jazyk:	angličtina
Zdroj:	Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2024 Aug 08; Vol. 12, pp. 1413688. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024).
DOI:	10.3389/fbioe.2024.1413688
Abstrakt:	Advancements in cell therapy have the potential to improve healthcare accessibility for eligible patients. However, there are still challenges in scaling production and reducing costs. These challenges involve various stakeholders such as the manufacturing facility, third-party logistics (3PL) company, and medical center. Proposed solutions tend to focus on individual companies rather than addressing the interconnectedness of the supply chain's challenges. The challenges can be categorized as barriers from product characteristics, regulatory requirements, or lagging infrastructure. Each barrier affects multiple stakeholders, especially during a boundary event like product handover. Therefore, solutions that only consider the objectives of one stakeholder fail to address underlying problems. This review examines the interconnecting cell therapy supply chain challenges and how they affect the multiple stakeholders involved. The authors consider whether proposed solutions impact individual stakeholders or the entire supply chain and discuss the benefits of stakeholder coordination-focused solutions such as integrated technologies and information tracking. The review highlights how coordination efforts allow for the implementation of widely-supported cell therapy supply solutions such as decentralized manufacturing through stakeholder collaboration. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Holland, Sohal, Nand and Hutmacher.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu